吡非尼酮(Pirfenidone) - 在研适应症：特发性肺纤维化，系统性硬化相关的间质性肺病，煤肺病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Pirfenidone (JAN/USAN/INN)、AMR-69、AP-01

+ [18]

靶点-

作用方式-

作用机制-

治疗领域

呼吸系统疾病其他疾病肿瘤+ [5]

在研适应症

特发性肺纤维化系统性硬化相关的间质性肺病煤肺病+ [13]

非在研适应症

急性心肌梗塞同种异体移植排斥反应外源性变应性肺泡炎+ [18]

原研机构

InterMune, Inc.

在研机构

Avalyn Pharma, Inc.

北京康蒂尼药业股份有限公司axunio Pharma GmbH

+ [9]

非在研机构

Hoffmann-La Roche, Inc.Bayer Schering Pharma AGRoche Pharma AG

+ [2]

权益机构

Marnac, Inc.

AFT Pharmaceuticals Ltd.

The Georgia Neurosurgical Institute

+ [5]

最高研发阶段批准上市

首次获批日期

日本 (2008-10-16),

特发性肺纤维化

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (美国)、快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (日本)、孤儿药 (韩国)

登录后查看时间轴

结构/序列

分子式C12H11NO

InChIKeyISWRGOKTTBVCFA-UHFFFAOYSA-N

CAS号53179-13-8

关联

198

项与吡非尼酮相关的临床试验

NCT06912763

/ Not yet recruiting临床2期IIT

Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)

To find out if adding medication can help treat or prevent lymphedema and/or fibrosis related to radiation therapy, in survivors of head and neck cancer. Researchers will compare these drugs to find the most effective therapy for preventing or limiting these side effects.

开始日期2025-09-18

申办/合作机构-

NCT06241560

/ Not yet recruiting临床2期

An Open-label, Single-group Trial to Evaluate the Effect of Pirfenidone on the Pharmacokinetics of a Single Oral Dose of BI 1015550

This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are 40 years and older. The purpose of this study is to find out whether a medicine called pirfenidone changes the amount of a medicine called BI 1015550 in the blood. Some people may take more than one medicine at a time. Therefore, it is important to understand how different medicines influence one another.
Participants take one dose of BI 1015550 as a tablet. Participants then take one tablet of pirfenidone 3 times a day for one week. The dose is then increased to 2 tablets 3 times a day for the second week. In the third week the dose is increased further to 3 tablets 3 times a day. Participants then take another dose of BI 1015550 as a tablet.
Participants are in the study for a little over 1 month. During this time, they visit the study site 15 times. Two of the visits include overnight stays at the study site. The study staff also contacts the participants by phone. During the visits, the doctors collect information about participants' health and take blood samples from the participants. They compare the amount of pirfenidone and BI 1015550 in the blood. Doctors also regularly check participants' health and take note of any unwanted effects.

开始日期2025-08-04

申办/合作机构

Boehringer Ingelheim GmbH

NCT07015398

/ Recruiting临床1期

A Phase 1, Two-Part, Open-Label Drug-Drug Interaction Study to Evaluate the Steady State Pharmacokinetics and Safety Following Co-Administration of Nalbuphine Extended-Release Tablets (NAL ER), and Pirfenidone or Nintedanib in Healthy Adult Subjects

The primary purpose of this study is to evaluate the effect of steady-state NAL ER on the pharmacokinetics (PK) of pirfenidone or nintedanib and the effect of steady-state pirfenidone or nintedanib on the PK of NAL ER in healthy participants.

开始日期2025-06-30

申办/合作机构

Trevi Therapeutics, Inc.

100 项与吡非尼酮相关的临床结果

登录后查看更多信息

100 项与吡非尼酮相关的转化医学

登录后查看更多信息

100 项与吡非尼酮相关的专利（医药）

登录后查看更多信息

2,725

项与吡非尼酮相关的文献（医药）

2025-12-01·Annals of Diagnostic Pathology

Relationship between fibroblastic foci and respiratory function: Does the abundance of fibroblastic foci reflect a recent decline in respiratory function?

Article

作者: Sakamoto, Ryo ; Nakajima, Daisuke ; Tanaka, Satona ; Handa, Tomohiro ; Date, Hiroshi ; Hamaji, Masatsugu ; Katsuragawa, Hiroyuki ; Haga, Hironori ; Ito, Hiroaki ; Yoshizawa, Akihiko

AIMS:

Fibroblastic foci (FF) are main findings in idiopathic pulmonary fibrosis (IPF) but are not specific to IPF. Pirfenidone and nintedanib are standard antifibrotic treatments for IPF and affect factors associated with fibroblasts. A proportion of interstitial lung diseases (ILDs) are progressive fibrosing ILDs (PF-ILDs). This progressive fibrosing phenotype includes various ILDs, including fibrotic hypersensitivity pneumonitis (FHP) and connective tissue disease-related ILD (CTD-ILD). We examined the relationship between FF and a relative decline in respiratory function.

METHODS AND RESULTS:

Among patients with lung transplantation (LT), those diagnosed with IPF, nonspecific interstitial pneumonia (NSIP), CTD-ILD, and FHP for whom respiratory function test results within 24 months before LT were retrospectively available were included (n = 67). Patients were classified as PF-ILD+ or PF-ILD- based on the criteria for the progression of a relative decline in the predicted value of forced vital capacity (FVC) within 24 months before LT. We classified FF into peripheral (pFF), alveolar (aFF), centrilobular (cFF), and distorted or dense fibrotic lesions (dFF). The number of FF/cm² at each location was counted, and its percentage was calculated. Spearman's rank correlation coefficient between a relative decline in %FVC and total FF/cm² in NSIP was 0.721. The dFF/cm² and dFF/total FF ratios were higher and the aFF/total FF ratio was lower in the PF-ILD+ group than in the PF-ILD- group.

CONCLUSION:

Total FF correlated with relative declines in %FVC in NSIP. Higher dFF/total FF ratios were associated with progressive status, and higher aFF/total FF ratios were associated with less progressive status.

2025-10-01·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Focal adhesion kinase inhibitors in fibrotic diseases therapy: Development and therapeutic potential

Review

作者: Wei, Wei ; Yu, Yan ; Su, Xingping ; Yue, Lin ; Xie, Yuting ; Liu, Zhihao ; Xue, Taixiong ; Ye, Tinghong ; Gan, Cailing

Organ fibrosis, characterized by dysregulated extracellular matrix deposition due to abnormal tissue repair, remains a significant challenge in medical research. Although nintedanib and pirfenidone have been approved for pulmonary fibrosis, effective treatments for hepatic, cardiac, and renal fibrosis remain markedly limited. The focal adhesion kinase (FAK) has been extensively implicated in the pathogenesis of organ fibrosis, with FAK kinase inhibition emerging as a pivotal therapeutic strategy for fibrosis modulation. In this review, we present a comprehensive analysis of FAK's biological functions in fibrotic progression and review preclinical advancements in FAK inhibitor development. We focus on the classification of FAK inhibitors, emphasizing their binding patterns, pharmacodynamic efficacy, and selectivity profiles from the perspective of pharmaceutical chemists. Additionally, we propose strategic frameworks for development of novel drugs targeting FAK for the treatment of fibrosis. The findings discussed in this review can guide the development of FAK inhibitors for treating organ fibrosis and underscore potential challenges in the drug development process.

2025-09-01·JOURNAL OF CONTROLLED RELEASE

Pulmonary surfactant-based pirfenidone-loaded nanovesicles for inhalation therapy of idiopathic pulmonary fibrosis

Article

作者: Choi, Byeong Hyeon ; Jang, Mincheol ; Kim, Chang Geun ; Jeon, Ok Hwa ; Park, Ji-Ho ; Oh, Chanhee ; Kim, Hyun Koo ; Kim, Kyungsu

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal chronic disease. One of the Food and Drug Administration (FDA)-approved therapies for IPF, oral pirfenidone (PFD), has limited clinical applications owing to its systemic side effects. In contrast to oral administration, inhaled therapy offers enhanced therapeutic efficacy at the target organ while minimizing systemic side effects. However, its application has challenges, such as limited drug delivery to the distal lung region and rapid clearance. In this study, we developed pulmonary surfactant (PS)-based PFD-loaded nanovesicles (PFD-PSNVs) for targeted delivery to the lung area and prolonged retention and examined their safety, stability, and antifibrotic efficacy. PFD-PSNVs were prepared using the thin-film hydration and extrusion method. The mean size and zeta potential of PFD-PSNVs were 149.7 ± 10.1 nm and - 31.3 ± 2.3 mV, respectively. An in vitro antifibrotic study showed that PFD-PSNVs inhibited the expression of fibrotic factors such as p-ERK, p-SMAD2/3, and α-SMA proteins on fibroblasts activated by transforming growth factor-β1. When inhaled in mice using a nebulizer, the PFD-PSNVs remained in lung tissues for 24 h, whereas Arikayce, an FDA-approved liposomal formulation for inhalation, was eliminated within 6 h. In a bleomycin sulfate-induced IPF mouse model, inhalation treatment with PFD-PSNVs significantly reduced collagen deposition (76.2 ± 4.1 %, p < 0.01) and α-SMA expression (60.8 ± 3.7 %, p < 0.05) compared with inhalation treatment with the PFD-loaded CtrlNV (PFD-CNVs) formulation and oral administration of PFD. These results indicate that PSNVs have great potential as an inhaled drug delivery system for the treatment of IPF.

297

项与吡非尼酮相关的新闻（医药）

2025-07-22

·FiercePharma

Avalyn raises $100M to advance inhaled versions of approved lung disease meds

Avalyn Pharma hopes its inhaled formulations of approved medicines will reduce systemic exposure and deliver medication directly to the site of disease. Avalyn Pharma has added on $100 million to accelerate novel inhaled versions of approved drugs for lung conditions.The company’s series D fundraise was led by Suvretta Capital Management and SR One and included 16 other investors, such as Novo Holdings, the investor fund best known as the controlling shareholder of Novo Nordisk.The new cash will go toward Avalyn’s clinical programs for pulmonary fibrosis, a lung-scarring condition that makes it harder to breathe. The Cambridge, Massachusetts-based business touts an inhaled formulation of pirfenidone—sold under many names as a pill for idiopathic pulmonary fibrosis (IPF), such as Pirespa—as one of its two lead programs.Dubbed AP01, Avalyn is currently assessing the candidate in a global phase 2b study, coded Mist, for patients with progressive pulmonary fibrosis. The trial is expected to enroll 300 participants and has a primary readout slated for April of next year, according to ClinicalTrials.gov.In an ongoing open-label extension of a phase 1b trial, the inhaled asset demonstrated safety and efficacy for more than four years, according to Avalyn.The company’s other lead program is another reformulation of an oral medication for IPF called nintedanib, which is marketed as Ofev and Vargatef. Avalyn’s inhaled version is known as AP02 and is expected to enter phase 2 testing for IPF.“Completing a significant round of financing despite the challenging market conditions is a testament to our innovative approach to developing potentially life-saving medicines for patients with pulmonary fibrosis,” Avalyn CEO Lyn Baranowski said in a July 22 release. The series D money raise follows a $175 million series C in 2023 and a $35.5 million series B in 2020.The company hopes its inhaled formulations of approved medicines will be able to reduce systemic exposure and deliver medication directly to the site of disease for pulmonary fibrosis patients. Avalyn is also advancing AP03, a next-gen inhaled fixed-dose combination of AP01 and AP02. To date, pairing the oral therapies hasn’t been possible because of the additive side effects. Avalyn is currently running preclinical studies for the asset.

临床2期

2025-07-22

·GlobeNewswire-Health Care

Avalyn Completes Oversubscribed $100 Million Series D Financing to Further Advance Clinical Development of Novel Inhaled Therapies for Pulmonary Fibrosis

Financing led by Suvretta Capital Management and SR One with participation from 16 additional healthcare investors Proceeds will support key clinical milestones across all of Avalyn’s pipeline programs CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced the closing of an oversubscribed $100 million Series D financing. The raise was co-led by Suvretta Capital Management and SR One, with participation from Novo Holdings A/S, F-Prime, Perceptive Xontogeny Venture Funds, Norwest, Eventide Asset Management, Wellington Management, Vida Ventures, Catalio Capital Management, RiverVest Venture Partners, Pivotal bioVenture Partners, TPG Biotech, Hamilton Square Partners Management, LP (HSq), Rock Springs Capital, Surveyor Capital (a Citadel company), funds and accounts advised by T. Rowe Price Associates, Inc., and Piper Heartland. In conjunction with the financing, David Friedman, M.D., Managing Director of Suvretta Capital Management, joined Avalyn’s Board of Directors and Diamantis Xylas, M.D., Partner and Head of Research of Catalio Capital Management, joined as a Board Observer. “Completing a significant round of financing despite the challenging market conditions is a testament to our innovative approach to developing potentially life-saving medicines for patients with pulmonary fibrosis,” said Lyn Baranowski, CEO of Avalyn. “We’ve made tremendous progress across our entire portfolio, completing Phase 1 clinical trials of AP02 and initiating a global Phase 2b clinical trial of AP01. With the support from an esteemed group of investors, we will continue the expeditious advancement of our clinical programs, while also bringing our third program into the clinic, all of which positions Avalyn for an exciting future of growth.” Proceeds will support key clinical milestones across Avalyn’s pipeline programs in pulmonary fibrosis, including the late-stage development of Avalyn’s lead programs: optimized inhaled formulations of pirfenidone (AP01) and nintedanib (AP02), as well as the advancement of the pirfenidone/nintedanib fixed dose combination (AP03) into Phase 1 clinical trials. AP01 is currently being evaluated in a global Phase 2b MIST trial in patients with progressive pulmonary fibrosis (PPF). In the completed Phase 1b ATLAS trial in patients with idiopathic pulmonary fibrosis (IPF), AP01 reduced lung function decline in a dose-responsive manner and demonstrated potential disease-modifying effects on fibrosis as observed by analyses of high-resolution computed tomography (HRCT) scans. In an ongoing open-label extension trial of patients with different forms of pulmonary fibrosis, AP01 has shown long-term safety and efficacy for more than 4.5 years. In addition, Avalyn recently completed Phase 1 trials of AP02, which demonstrated safety and tolerability at all dose levels and a favorable pharmacokinetic profile. The company plans to initiate a Phase 2 clinical trial for AP02 in patients with IPF. “Avalyn is at an exciting point in its evolution with multiple transformative product opportunities in clinical development, each with significant commercial potential,” said David Friedman, M.D., Managing Director of Suvretta Capital Management. “The clinical data generated to date for AP01 and AP02 are clinically compelling on their own, but when compared to the data for the currently approved oral treatments, they support the potential for Avalyn to achieve disease modification for patients with pulmonary fibrosis. We are thrilled to back such an exceptional team translating breakthrough science into real clinical impact, and what we believe will be a category-changing company in respiratory medicine.” “Lyn and team are executing a clear growth strategy for Avalyn rooted in both clinical insight and operational excellence,” said Jill Carroll, Partner at SR One and an Avalyn Board Director. “On behalf of the entire Board, we’re proud of their patient-focused approach and commitment to innovation and scientific rigor, which positions this company to redefine the future of what’s possible for patients suffering from pulmonary fibrosis.” Avalyn’s earlier-stage pipeline includes AP03, a next-generation inhaled fixed-dose combination of AP01 and AP02. Clinical data indicate that the combination of pirfenidone and nintedanib may offer additive, or even synergistic, efficacy advantages over either product alone. Combining these oral therapies has not been feasible due to the additive side effects when taken together. Inhaled delivery has the potential to solve the tolerability challenges of the oral antifibrotics, enabling Avalyn to combine these medicines effectively for the first time. Avalyn is advancing IND-enabling studies for AP03 and is planning a Phase 1 clinical trial. About Avalyn PharmaAvalyn is reimagining the future of pulmonary fibrosis treatment with a pipeline of new inhaled formulations of approved medicines designed to reduce systemic exposure and deliver medication directly to the site of disease. Pulmonary fibrosis is characterized by scarring of lung tissue, decline in lung function, and reduced exercise capacity and quality of life, and is associated with increased mortality. Currently approved therapeutic options slow pulmonary fibrosis progression but are associated with significant toxicities that restrict their use and dosing. Avalyn’s inhaled approach tackles the underlying pathophysiology of pulmonary fibrosis at its source and is designed to reduce systemic exposure and deliver medication directly to the site of disease. Avalyn’s AP01 is an optimized inhaled formulation of pirfenidone, currently being studied in the ongoing MIST Phase 2b study in progressive pulmonary fibrosis (PPF). AP01 has been assessed in over 150 individuals with different forms of pulmonary fibrosis and demonstrated clinical proof-of-concept with improved efficacy and safety compared to historical data with existing therapies. The company completed two Phase 1 studies for AP02, inhaled nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). For more information, please visit avalynpharma.com and follow us on LinkedIn. Investor Contact:Alex Straus, THRUST alex@thrustsc.comir@avalynpharma.com Media Contact:Kat Lippincott, Deerfield Groupkat.lippincott@deerfieldgroup.commedia@avalynpharma.com

临床1期临床2期临床结果

2025-07-22

·Firstwordpharma

Avalyn pulls in $100M to challenge oral lung fibrosis drugs with inhaled rivals

Avalyn Pharma closed an oversubscribed $100 million series D financing round to advance its pipeline of inhaled therapies for pulmonary fibrosis, the company announced Tuesday. The round was co-led by Suvretta Capital Management and SR One, with participation from a slate of additional healthcare investors including Novo Holdings and F-Prime.The financing comes as Avalyn is looking to challenge the current standard of care — oral medications such as Boehringer Ingelheim's Ofev (nintedanib) and Roche's Esbriet (pirfenidone) — with targeted inhaled versions that could be both safer and more effective.While existing drugs can slow lung scarring, their side effects, mainly due to the high doses needed to compensate for inefficient gut absorption, can limit their use. By delivering drugs directly to the lungs in smaller doses, Avalyn believes it can sidestep the side effects that hinder current therapies without compromising on efficacy."Completing a significant round of financing despite the challenging market conditions is a testament to our innovative approach," said CEO Lyn Baranowski in a company release.Breathing new life into old drugsAvalyn's lead programme, AP01, is an inhaled formulation of pirfenidone that is currently being evaluated in the Phase IIb MIST trial for progressive pulmonary fibrosis. Earlier this year, it teamed up with image analytics firm Qureight to help measure efficacy in the trial.In the previous Phase Ib ATLAS study, AP01 showed dose-dependent slowing of lung function decline in patients with idiopathic pulmonary fibrosis (IPF). Further, AP01 has also demonstrated sustained safety and antifibrotic benefits in an open-label extension, with some patients on treatment for over 4.5 years.Its second programme, AP02, is an inhaled version of nintedanib that recently completed Phase I trials showing safety and favourable pharmacokinetics. The company plans to initiate a Phase II study for AP02 in patients with IPF.Combined punchMeanwhile, Avalyn's third programme, AP03, is a preclinical fixed-dose combination of its two lead compounds that could potentially offer synergistic benefits. "Combining these oral therapies has not been feasible due to the additive side effects when taken together," the company said. It plans to move AP03 into the clinic following IND-enabling studies."Avalyn is at an exciting point in its evolution with multiple transformative product opportunities in clinical development, each with significant commercial potential," said David Friedman, managing director of Suvretta, who joined Avalyn's board in conjunction with the financing. Data for AP01 and AP02 are "clinically compelling on their own, but when compared to the data for the currently approved oral treatments, they support the potential for Avalyn to achieve disease modification for patients with pulmonary fibrosis."Avalyn raised $175 million in 2023 to advance AP01 and AP02.

临床2期临床1期

100 项与吡非尼酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01583	吡非尼酮	L04AX05	DB04951

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
特发性肺纤维化	日本	Shionogi & Co., Ltd.	2008-10-16

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
系统性硬化相关的间质性肺病	临床3期	中国	GNI Group Ltd.	2023-05-29
煤肺病	临床3期	-	北京康蒂尼药业股份有限公司	2022-04-15
尘肺病	临床3期	-	北京康蒂尼药业股份有限公司	2022-04-15
矽肺	临床3期	-	北京康蒂尼药业股份有限公司	2022-04-15
皮肌炎	临床3期	中国	北京康蒂尼药业股份有限公司	2018-06-01
间质性肺疾病	临床3期	中国	北京康蒂尼药业股份有限公司	2017-10-31
硬化肼胝症	临床3期	中国	北京康蒂尼药业股份有限公司	2017-10-31
进展性肺纤维化	临床2期	美国	Avalyn Pharma, Inc.	2024-04-03
进展性肺纤维化	临床2期	阿根廷	Avalyn Pharma, Inc.	2024-04-03
进展性肺纤维化	临床2期	澳大利亚	Avalyn Pharma, Inc.	2024-04-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2025	N/A	特发性肺纤维化	4,529	Pirfenidone	鏇衊遞選觸壓窪鏇衊蓋(餘齋鏇蓋願餘醖襯憲網) = 範繭夢繭繭鏇鹽壓簾願蓋蓋鬱繭鏇鏇鏇鏇糧簾 (糧鑰襯壓製網選淵艱鹽 )	积极	2025-05-30
				Non-Pirfenidone	鏇衊遞選觸壓窪鏇衊蓋(餘齋鏇蓋願餘醖襯憲網) = 網醖顧醖製餘範獵憲憲蓋蓋鬱繭鏇鏇鏇鏇糧簾 (糧鑰襯壓製網選淵艱鹽 )
AP01-002 (ATLAS) (ATS2025)	N/A	-	91	50 mg AP01 once daily	窪夢顧鏇鏇製醖襯襯醖(鏇衊遞夢壓觸壓網夢築) = 網鑰簾範襯鹹憲簾願醖鹹鑰淵鹹淵鬱窪積衊構 (遞糧憲鹽醖網鹹獵積積 )	积极	2025-05-16
				100 mg AP01 twice daily	窪夢顧鏇鏇製醖襯襯醖(鏇衊遞夢壓觸壓網夢築) = 簾夢製鹽鬱遞構衊鏇襯鹹鑰淵鹹淵鬱窪積衊構 (遞糧憲鹽醖網鹹獵積積 ) 更多
ATS2025	N/A	进展性肺纤维化	33	Pirfenidone	鹹鹽觸鏇鑰膚齋選蓋範(觸繭鬱願齋繭淵願顧壓) = 21.2% 鹽選廠獵鏇淵構顧廠艱 (築廠夢獵膚膚選繭鹽窪 ) 更多	积极	2025-05-16
ATLAS Phase 1b Trial (ATS2025)	临床1期	特发性肺纤维化	64	Nebulised AP01 50mg QD	遞廠淵膚蓋醖鬱鏇夢願(糧壓蓋鬱顧窪鏇獵鹹糧) = 糧網餘築觸餘鹽襯淵範願齋鹹製夢構淵選壓餘 (觸積衊製構蓋淵鏇鹹齋 ) 更多	积极	2025-05-16
				Nebulised AP01 100mg BID	遞廠淵膚蓋醖鬱鏇夢願(糧壓蓋鬱顧窪鏇獵鹹糧) = 願艱鏇繭鹹淵顧鏇齋艱願齋鹹製夢構淵選壓餘 (觸積衊製構蓋淵鏇鹹齋 ) 更多
ATS2025	N/A	特发性肺纤维化	-	Full dose antifibrotic therapy	鑰憲衊窪積憲範築淵鑰(繭鹹繭鏇蓋窪壓觸顧蓋) = 鹹夢憲鹽選願構構艱窪壓廠範鬱蓋遞鏇廠艱簾 (鬱衊顧艱構網簾醖鹹鏇 )	积极	2025-05-16
				Reduced dose antifibrotic therapy	鑰憲衊窪積憲範築淵鑰(繭鹹繭鏇蓋窪壓觸顧蓋) = 衊製鑰構窪淵築淵齋膚壓廠範鬱蓋遞鏇廠艱簾 (鬱衊顧艱構網簾醖鹹鏇 )
ASTRO2024	临床2期	辐射损伤	134	Pirfenidone plus standard therapy	鑰鹽鏇鏇壓鑰繭鹽鏇選(獵鑰夢獵窪廠齋繭襯鏇) = 衊鬱鏇遞膚範鬱選簾觸艱鹹製鑰餘鬱鹽願簾網 (願獵襯糧築範鹹淵鹽淵 ) 更多	积极	2024-10-01
WCLC2024	临床2期	肺损伤 PD-1 inhibitors	14	Pirfenidone	網顧簾構壓築壓襯顧構(遞廠醖顧糧築蓋壓夢願) = Pirfenidone-related adverse events (≤ grade 2) occurred in 7 patients, including six gastrointestinal reactions and one photosensitivity reaction 選製淵遞壓餘製艱艱鹽 (憲蓋齋淵衊繭顧壓選醖 )	积极	2024-09-07
				Immune Checkpoint Inhibitors
ATS2024	N/A	-	-	50mg AP01 once daily	夢壓範築築齋膚築糧觸(範積餘網構鏇淵淵窪餘) = AE were present in 93.3% of patients overall, with AE frequencies similar across cohorts 膚製餘選築鏇廠衊壓餘 (衊鏇鹹憲簾醖糧襯鹹鹽 )	-	2024-05-19
				100mg AP01 twice daily
ATS2024	N/A	疾病进展	-	AP01 100 mg BID	製願蓋艱觸顧顧鏇範艱(獵憲齋網積遞構範餘膚) = 鹹廠網鹽積憲願鏇糧製鬱鹹簾範鏇構觸築襯艱 (廠衊廠糧壓膚網簾顧艱 )	-	2024-05-19
				AP01 50 mg QD	製願蓋艱觸顧顧鏇範艱(獵憲齋網積遞構範餘膚) = 廠夢壓壓艱蓋糧網鏇範鬱鹹簾範鏇構觸築襯艱 (廠衊廠糧壓膚網簾顧艱 )
ATLAS AP01 (ATS2024)	临床1期	特发性肺纤维化 WRVS \| e-Lung volume	63	Nebulised Pirfenidone 100mg BD	顧膚簾衊遞構簾襯膚網(膚顧餘餘鬱窪鏇齋廠壓) = 衊衊願衊鑰齋構蓋壓鬱壓簾淵鹹範顧廠淵鏇構 (鏇襯製簾齋艱範鹹網壓, -5.5% ~ +3.9) 更多	积极	2024-05-19
				Nebulised Pirfenidone 50mg OD	顧膚簾衊遞構簾襯膚網(膚顧餘餘鬱窪鏇齋廠壓) = 鹽構鹹餘糧獵鏇醖積積壓簾淵鹹範顧廠淵鏇構 (鏇襯製簾齋艱範鹹網壓, 1.2% ~ 9.5%) 更多